Efficacy and Safety of a Novel Anti-HER2 Therapeutic Antibody RC48 in Patients with HER2-Overexpressing, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer: A Single-Arm Phase II Study

    October 2021 in “ Cancer Communications ”
    Zhi Peng, Tianshu Liu, Jia Wei, Airong Wang, Yifu He, Liuzhong Yang, Xizhi Zhang, Nanfeng Fan, Suxia Luo, Zhen Li, Kangsheng Gu, Jianwei Lu, Jianming Xu, Qingxia Fan, Rui‐Hua Xu, Liangming Zhang, Enxiao Li, Yuping Sun, Guohua Yu, Chunmei Bai, Yong Liu, Jiangzheng Zeng, Jieer Ying, Xinjun Liang, Nong Xu, Chao Gao, Yongqian Shu, Dong Ma, Guanghai Dai, Shengmian Li, Ting Deng, Yuehong Cui, Jianmin Fang, Yi Ba, Lin Shen
    TLDR RC48 shows promise for treating certain advanced cancers, but more research is needed.
    The study assessed the efficacy and safety of the novel anti-HER2 antibody RC48 in 125 patients with HER2-overexpressing, advanced gastric or gastroesophageal junction cancer. It found an objective response rate of 24.8%, with median progression-free survival of 4.1 months and overall survival of 7.9 months. Common adverse events included decreased white blood cell count, asthenia, and hair loss, with serious adverse events in 36% of patients. The study concluded that RC48 showed promising activity with manageable safety, suggesting its potential application for this patient population, though further trials were recommended.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results